Deoxycholic Acid-d4
(Synonyms: 去氧胆酸 d4) 目录号 : GC47187An internal standard for the quantification of deoxycholic acid
Cas No.:112076-61-6
Sample solution is provided at 25 µL, 10mM.
Deoxycholic acid-d4 (DCA-d4) is intended for use as an internal standard for the quantification of DCA by GC- or LC-MS. DCA is a secondary bile acid that is formed via microbial transformation of cholic acid in the colon.1 It can be conjugated to glycine or taurine to produce glycodeoxycholic acid or taurodeoxycholic acid , respectively, in hepatocytes.1,2,3 DCA (0.2% v/v) inhibits spore germination induced by taurocholic acid in seven C. difficile strains, as well as inhibits growth and decreases the cytotoxicity of C. difficile culture supernatants to Vero cells when used at a concentration of 0.02% v/v.1 It inhibits ionizing radiation-induced p53-dependent transcription in a reporter assay using HCT116 cells when used at a concentration of 200 µM.4 Fecal and intestinal tissue levels of DCA are increased in a rat model of high-fat diet-induced obesity compared with rats fed a normal diet.5 Increased serum DCA levels have been found in patients with colorectal cancer.6
1.Thanissery, R., Winston, J.A., and Theriot, C.M.Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acidsAnaerobe4586-100(2017) 2.Schmid, A., Neumann, H., Karrasch, T., et al.Bile acid metabolome after an oral lipid tolerance test by liquid chromatography-tandem mass spectrometry (LC-MS/MS)PLoS One11(2)e0148869(2016) 3.šarenac, T.M., and Mikov, M.Bile acid synthesis: From nature to the chemical modification and synthesis and their applications as drugs and nutrientsFront. Pharmacol.9939(2018) 4.Qiao, D., Gaitonde, S.V., Qi, W., et al.Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradationCarcinogenesis22(6)957-964(2001) 5.Lin, H., An, Y., Tang, H., et al.Alterations of bile acids and gut microbiota in obesity induced by high fat diet in rat modelJ. Agric. Food Chem.67(13)3624-3632(2019) 6.BayerdÖrffer, E., Mannes, G.A., Richter, W.O., et al.Increased serum deoxycholic acid levels in men with colorectal adenomasGastroenterology104(1)145-151(1993)
Cas No. | 112076-61-6 | SDF | |
别名 | 去氧胆酸 d4 | ||
Canonical SMILES | O[C@@H]1C([2H])([2H])C[C@@]2(C)[C@@](CC[C@]3([H])[C@]2([H])C[C@H](O)[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCC(O)=O)([H])C1([2H])[2H] | ||
分子式 | C24H36D4O4 | 分子量 | 396.6 |
溶解度 | DMF: 30 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 20 mg/ml,Ethanol: 20 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.5214 mL | 12.6072 mL | 25.2143 mL |
5 mM | 0.5043 mL | 2.5214 mL | 5.0429 mL |
10 mM | 0.2521 mL | 1.2607 mL | 2.5214 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet